AMSBIO has published an interview with Professor Marius Wernig of Stanford University, Pathology Stem Cell Institute, who discusses what may be the world’s first widely applicable cure for Epidermolysis Bullosa (EB).
This rare genetic disease causes chronic and incredibly painful skin sores that often lead to an aggressive form of skin cancer and death.
While various cell therapy approaches have been attempted, Prof. Wernig and his collaborators identified the need for induced pluripotent stem cells (iPSCs) and how they could be used to treat EB in a more effective, applicable and commercially viable way.
In the past, the only way for Professor Wernig’s research group to grow iPSC cells with a normal karyotype for longer periods of time was on mouse feeder cells with serum. This combination of co-culture of mouse cells and undefined bovine serum pool was not an appropriate methodology because it was nearly impossible to perform according to FDA safety standards.
Professor Wernig describes how StemFit® Basic03 clinical-grade stem cell culture medium, available from AMSBIO, enabled his research group to safely expand their cells using an FDA-compliant protocol. Although there are still hurdles to climb before a cure for EB is fully realized, the use of StemFit® Basic03 has solved the challenge of reproducible growth of clinical grade iPSCs.
Read the full interview.
Completely free of components of animal and human origin StemFit® Basic03 provides highly stable and reproducible culture conditions for induced pluripotent stem cells and embryonic stem cells under no-feed conditions during reprogramming, expansion and differentiation phases stem cell culture. StemFit® Basic03 combines high colony forming efficiency with lower than standard media volume consumption to deliver cost effective colony expansion compared to leading competitors.
More information online